Eli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to an average ...

Despite the Trump administration's tariff threats and pressure to move more manufacturing to the U.S., the push to raise ...

Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook. Read why I rate NVO stock a ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

O'Reilly Automotive Inc. is suing the three major pharmacy benefit managers in the U.S., as well as the three major insulin manufacturers.

Novavax expects post-marketing COVID study to cost up to $90M; New Novo CEO set to reallocate struggling drugmaker’s resources; WSJ editorial board argues against Trump’s MFN proposal.

Novo Nordisk A/S (NYSE:NVO) is one of the top NYSE stocks with the highest upside potential. On August 5, UBS downgraded Novo ...

Eli Lilly and Company (NYSE: LLY) is one of the stocks in Jim Cramer’s game plan for this week. Cramer highlighted that his ...

Novo Nordisk ( NVO -4.02%) stock imitated the company's leading product on Wednesday by slimming down in price. The Danish pharmaceutical's shares lost nearly 4% of their value following its latest ...

The news comes days after Novo cut its full-year outlook due to rising competition from copycat compounders, and named a new ...